GSK PLC on Thursday welcomed a court ruling in Florida state court that found in the drug makers favour.
The London-based company said the court excluded plaintiff’s experts’ general and specific causation testimony that ranitidine, known as Zantac, was a significant risk for Wilson’s prostate cancer.
GSK said it welcomed the Daubert’s ruling and will now seek dismissal of the upcoming Wilson case in Florida, whereby plaintiffs alleged a causal link between ranitidine and prostate cancer.
The Daubert standard in the US provides criteria for evaluating whether expert testimony is admissible.
‘Today’s decision echoes the December 2022 ruling by Judge Rosenberg in the federal multidistrict litigation, which rejected all expert evidence put forward by the plaintiffs and dismissed all MDL cases alleging bladder, esophageal, gastric, liver, or pancreatic cancer.’ the company said.
Zantac was a heartburn drug that was pulled off the market in 2020 at the request of the US Food & Drug Administration, after low levels of a ‘probable carcinogen’ were found in samples. The carcinogen, known as NDMA, is not harmful in very small amounts. However, tests showed that there were excessive quantities of NDMA in ranitidine, otherwise known as Zantac. Multiple litigations have followed.
GSK shares closed 0.4% lower at 1,591.50 pence each on Thursday in London, before the announcement.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
